Structure Therapeutics

Biotech & Life Sciences · South San Francisco, United States · Founded 2016 · IPO 2023

Structure Therapeutics is a clinical-stage biopharmaceutical company that specializes in the discovery and development of oral small molecule therapeutics for the treatment of chronic metabolic diseases. The company leverages its expertise in structure-based drug design to create more accessible and effective treatments. Operating in the biopharmaceutical market, Structure Therapeutics focuses on developing innovative drugs for a range of metabolic disorders. Its business model is centered on a science-driven approach to drug discovery, advancing promising candidates through clinical trials. The company generates revenue through the development and commercialization of its proprietary drug candidates. Keywords: biopharmaceutical, clinical-stage, drug design, metabolic diseases, oral therapeutics, small molecules, structure-based, GLP-1, GPCR, chronic illness

Valuation $1.96B

Revenue $38M

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier Colt$25–100M revenue

Investors

22 investors on Structure Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 12 investors entered at this stage

Qiming Venture Partners

Eight Roads Ventures

Sequoia

Citadel

Janus Henderson Investors

Monashee Capital Corp.

Sage Partners

Terra Magnum Capital Partners

Woodline Partners

Stork Capital

Deep Track Capital

Piper Heartland Healthcare Capital

Series B+ 10 investors entered at this stage

Monashee Capital Corp.

Terra Magnum Capital Partners

Piper Heartland Healthcare Capital

Sage Partners

Citadel

Janus Henderson Investors

Sequoia

Deep Track Capital

Woodline Partners

Stork Capital

Global footprint

Where Structure Therapeutics has talent and traffic

Workforce by country

7 countries with
team presence

🇺🇸 United States75.3%

🇨🇳 China20%

🇬🇧 United Kingdom1.3%

🇨🇭 Switzerland0.7%

🇳🇱 Netherlands0.7%

Top 5 of 7 shown

Web traffic by country

13K monthly visits
across markets

🇺🇸 United States54.6%

🏳️ Korea14.6%

🏳️ Republic of13.1%

🇦🇺 Australia9.2%

🇮🇳 India6.2%

Top 5 markets shown

Talent graph

The shape of Structure Therapeutics's talent

Dealroom maps Structure Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

8 standout operatorsDealroom-flagged across the org

2 AI specialistsincl. 1 core researchers

239 employees mappedperson by person

DimensionScore

AI Talentlive

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Structure Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Structure Therapeutics

An AI-synthesized read of the highest-engagement posts about Structure Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Structure Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles